WO2011095837A1 - Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge - Google Patents

Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge Download PDF

Info

Publication number
WO2011095837A1
WO2011095837A1 PCT/IB2010/050446 IB2010050446W WO2011095837A1 WO 2011095837 A1 WO2011095837 A1 WO 2011095837A1 IB 2010050446 W IB2010050446 W IB 2010050446W WO 2011095837 A1 WO2011095837 A1 WO 2011095837A1
Authority
WO
WIPO (PCT)
Prior art keywords
macular degeneration
age
related macular
treatment
amd
Prior art date
Application number
PCT/IB2010/050446
Other languages
English (en)
Inventor
Fernando Moreno Egea
Mario Fernandez Montes
Original Assignee
Soluciones Extractivas Alimentarias, S.L. Solutex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soluciones Extractivas Alimentarias, S.L. Solutex filed Critical Soluciones Extractivas Alimentarias, S.L. Solutex
Priority to EP10714963A priority Critical patent/EP2531184A1/fr
Priority to PCT/IB2010/050446 priority patent/WO2011095837A1/fr
Publication of WO2011095837A1 publication Critical patent/WO2011095837A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Definitions

  • the retina has one of the highest concentrations of omega-3 fatty acids in the body.
  • the macula is an oval-shaped highly pigmented yellow spot (its Latin definition means spot or stain) roughly in the center of the retina of the human eye. It has a diameter of less than 10 mm and is often histologically defined as having two or more layers of ganglion cells.
  • the macula allows us to appreciate details and perform tasks that require central vision like reading.
  • Macular degeneration is a medical condition usually of older adults which results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. It occurs in “dry” and "wet” forms. Macular degeneration can make it difficult or impossible to read or recognize faces, although enough peripheral vision remains to allow other activities of daily life.
  • AMD age-related macular degeneration
  • AMD AMD 90 percent of AMD patients and usually begins with the formation of tiny yellow deposits called drusen in the macula. Drusen usually do not cause serious loss of vision, but can cause distortion of vision. However, sometimes drusen will cause the macula to thin and break down, slowly leading to vision loss.
  • the wet form of AMD occurs in about 10 percent of AMD patients. It is caused by the growth of abnormal blood vessels beneath the macula that can leak fluid and blood. The wet form of AMD typically causes significant vision problems in the affected eye and can progress very rapidly, causing permanent central vision loss. The exact cause of AMD is not known, although AMD may be hereditary. Currently, there is no effective therapy that is capable of significantly slowing the degenerative progression of macular degeneration.
  • Oxidative processes have been proposed to play at least a contributing role in a steadily growing number of diseases, such as neurodegenerative disorders, cataract, and age-related macular degeneration (AMD).
  • ALD age-related macular degeneration
  • oxidative stress free radicals
  • oxygen which is necessary for life in providing aerobic respiration, may also be toxic.
  • the outer retina and, in particular, the outer segments of photoreceptors contain high concentrations of polyunsaturated fatty acids (PUFAs) in the membranes. This region is also exposed to a relatively high oxygen tension which is close to that found in arterial blood.
  • PUFAs polyunsaturated fatty acids
  • ROP is a disease of the eyes of prematurely born infants in which the retinal blood vessels increase in number and branch excessively, sometimes leading to bleeding or scarring. Infants who progress to a severe form of ROP are in danger of becoming permanently blind.
  • diabetic retinopathy a disease in which blood vessels swell and leak fluid or grow abnormally on the surface of the retina
  • AMD age-related macular degeneration
  • Omega-3 fatty acids create chemical compounds known as bioactive mediators, which protect against the growth of abnormal blood vessels, a condition that characterizes some forms of retinopathy. In part, this occurs because these mediators suppress a type of inflammatory protein called tumor necrosis factor alpha (TNF-alpha). TNF-alpha is found in one type of cell, called microglia, that can be closely associated with retinal blood vessels.
  • TNF-alpha tumor necrosis factor alpha
  • AREDS Age-Related Eye Disease Study
  • DHA docosahexaenoic acid
  • AREDS 2 is a multi-center randomized trial designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and/or omega -3 LCPUFAs (DHA and EPA) for the treatment of AMD and cataract.
  • macular xanthophylls lutein and zeaxanthin
  • omega -3 LCPUFAs DHA and EPA
  • beta-carotene may be supplemented to a patient using 110 a commercially available form of beta-carotene, suggesting one such product sold by Hoffman-LaRoche under the trademark "Solatene.”
  • Synthetic beta- carotene consists of one molecule called “bans beta carotene.”
  • synthetic beta-carotene may cause an increased risk of lung cancer and disease of the blood vessels.
  • This invention describes a method to prevent the onset or to slow down the
  • DHA is a ligand for the Peroxisome Proliferator Activated Receptor gamma (PPARy), which is expressed in the retinal pigment epithelium (RPE), a pigmented cell layer that nourishes retinal visual cells and is involved in the phagocytosis of the outer segments of
  • RPE retinal pigment epithelium
  • PPARs Peroxisome Proliferator-activated Receptors
  • PPARs are a group of nuclear receptors proteins that work as transcription factors regulating the expression of genes. PPARs are involved, among others, in lipid and glucidic metabolism and 130 accordingly to these functions synthetic agonists (thiazolidinediones and fibrates) have been marketed for years for treatment of type 2 diabetes or hypercholesterolemia.
  • PPARs in general are members of a superfamily of ligand-activated transcription factors and as stated above, DHA is one of their naturally occurring ligands, 135 specifically for the subtype PPARy.
  • PPARy play an important role in lipid degeneration, in regulation of reactive oxygen species and in the regulation of the chemical signal named "vascular endothelial growth factor” (VEGF). All of these molecules have been referred as related to the pathogenesis of age related macular degeneration.
  • VEGF vascular endothelial growth factor
  • RPE retinal pigment epithelium
  • ROS reactive oxygen species
  • PPARy upregulates the expression of antioxidant genes such as glutamate cysteine ligase and heme-oxidase-1.
  • those antioxidants work through 165 MAPK kinase patways to curb ROS (S. Qin, A. P. McLaughlin, and G. W. De Vries,
  • hypoxia increases the secretion of vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • PPARy has an antagonistic relationship with VEGF, inhibiting therefore the neovascularization typical of the wet form of macular degeneration (T.Murata et al., "Peroxisome 175 proliferator-activated receptor-)/ ligands inhibit choroidal neovascularization,”/ni e5i/ ' gai/Ve Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2309-2317, 2000).
  • one aspect of the invention is related to high concentrates of docosahexaenoic acid (DHA) ethyl esters in order to maintain the levels of DHA in 180 the photoreceptor cells and thus improving the retinal pigment, known as rhodopsine, regeneration, preserving the ability of the retina to process images.
  • DHA docosahexaenoic acid
  • compositions comprising a therapeutically effective amount of zeaxanthine and docosahexaenoic acid (DHA) 185 are disclosed.
  • the invention is based, in part, on the synergistic effect between docosahexaenoic acid (DHA) and carotenoids.
  • Lutein and zeaxanthin belong to the xanthophyll class of carotenoids, also known as oxycarotenoids, which are natural fat-soluble yellowish pigments.
  • Zeaxanthin is derived exclusively from dietary sources, such as dark green leafy vegetables 190 and oranges. Zeaxanthin is believed to rebuild the ocular pigment density of the macula, thereby protecting against radiation damage of the retina, in the same way as protects plants from solar radiation.
  • Lutein and zeaxanthin are transported within the blood primarily on the surface of HDL (about 53%), but also on LDL (about 31%) and VLDL (about 16%).
  • zeaxanthin and DHA appear to alter the lipoprotein profile, resulting in increase zeaxanthin concentration in the macula.
  • supplemental zeaxanthin and DHA can be used to prevent or slow the progression of AMD.
  • the composition should contain at least 2mg per dose.
  • Table 1 presents the minimum contains in the formulation:
  • Vitamin E tocopherols 0,4 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur une composition contenant des esters éthyliques du DHA de pureté supérieure à 80 % en poids pour la prévention et le traitement de la dégénérescence maculaire liée à l'âge, qui utilise le récepteur activé par les proliférateurs de peroxysomes gamma (PPARγ) comme cible.
PCT/IB2010/050446 2010-02-02 2010-02-02 Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge WO2011095837A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10714963A EP2531184A1 (fr) 2010-02-02 2010-02-02 Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge
PCT/IB2010/050446 WO2011095837A1 (fr) 2010-02-02 2010-02-02 Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/050446 WO2011095837A1 (fr) 2010-02-02 2010-02-02 Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge

Publications (1)

Publication Number Publication Date
WO2011095837A1 true WO2011095837A1 (fr) 2011-08-11

Family

ID=42710578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/050446 WO2011095837A1 (fr) 2010-02-02 2010-02-02 Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge

Country Status (2)

Country Link
EP (1) EP2531184A1 (fr)
WO (1) WO2011095837A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4138779A4 (fr) * 2020-04-21 2024-05-22 University of Massachusetts Méthodes et compositions pour le traitement de la dégénérescence maculaire liée à l'âge

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249821A1 (en) * 2004-05-08 2005-11-10 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
WO2006097267A1 (fr) * 2005-03-16 2006-09-21 Novartis Ag Melanges vitamines
WO2006116755A2 (fr) * 2005-04-28 2006-11-02 Trustees Of Tufts College Effets synergiques de l'acide docosahexaenoique (dha) et de l'absorbtion de carotenoides sur les fonctions cognitives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249821A1 (en) * 2004-05-08 2005-11-10 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
WO2006097267A1 (fr) * 2005-03-16 2006-09-21 Novartis Ag Melanges vitamines
WO2006116755A2 (fr) * 2005-04-28 2006-11-02 Trustees Of Tufts College Effets synergiques de l'acide docosahexaenoique (dha) et de l'absorbtion de carotenoides sur les fonctions cognitives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B. S. WINKLER; M. E. BOULTON; J. D. GOTTSCH; P. STERNBERG: "Oxidative damage and age-related macular degeneration", MOLECULAR VISION, vol. 5, 1999, pages 32
DE JONG: "PTVM. Age related macular degeneration", NEW ENGLAND JOURNAL OF MEDICINE, vol. 355, no. 14, 2006, pages 1474 - 1485
JOHN PAUL SANGIOVANNI ET AL.: "The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina", PROGRESS IN RETINAL AND EYE RESEARCH, vol. 24, no. 1, January 2005 (2005-01-01), pages 87 - 138
MARTINEZ M: "Restoring the DHA levels in the brains of Zellweger patients", JOURNAL OF MOLECULAR NEUROSCIENCE, BIRKHAEUSER, CAMBRIDGE, MA, US, vol. 16, no. 2-3, 1 April 2001 (2001-04-01), pages 309 - 316, XP009138759, ISSN: 0895-8696 *
MILLER ET AL.: "High Dosage Vitamin E Supplementation May Increase All-I cause Mortality", ANN. INTERN. MED., 10 November 2004 (2004-11-10)
PARKER RS.: "Absorption, metabolism, and transport of carotenoids", FASEB J., vol. 10, 1996, pages 542 - 551
S. QIN; A. P. MCLAUGHLIN; G. W. DE VRIES: "Protection of RPE cells from oxidative injury by 15-deoxy-A12,14-prostag)andin J2 by augmenting GSH and activating MAPK", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 47, no. 11, 2006, pages 5098 - 5105
T.MURATA ET AL.: "Peroxisome proliferator-activated receptor-y ligands inhibit choroidal neovascularization", LNVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 41, no. 8, 2000, pages 2309 - 2317

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4138779A4 (fr) * 2020-04-21 2024-05-22 University of Massachusetts Méthodes et compositions pour le traitement de la dégénérescence maculaire liée à l'âge

Also Published As

Publication number Publication date
EP2531184A1 (fr) 2012-12-12

Similar Documents

Publication Publication Date Title
Sunkireddy et al. Natural antioxidant biomolecules promises future nanomedicine based therapy for cataract
KR101660195B1 (ko) 크릴 오일과 반응한 아스타잔틴 조성물 및 관련 방법
US9849096B2 (en) Neuroprotective effect of carotenoids in brain
US10881638B2 (en) Eye health composition
JP2009515821A (ja) 眼疾患を治療するための組成物
US9351982B2 (en) Krill oil and reacted astaxanthin composition and associated method
JP6408702B2 (ja) 抗酸化点眼薬
JP2017511380A (ja) 脂溶性栄養素の糖尿病性眼疾患への効果
WO2014023082A1 (fr) Composition utilisée pour améliorer la densité de pigment maculaire dans les yeux et pour prévenir ou traiter la dégénérescence maculaire liée à l'âge
US20130045940A1 (en) Composition comprising as active ingredient l-carnitine in combination with a solar filter, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
Sarialtin et al. An overview on the role of macular xanthophylls in ocular diseases
JP2007521274A (ja) 複数成分の組み合わせを用いる加齢性黄斑変性の処置
EP2531184A1 (fr) Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge
JPWO2006030907A1 (ja) 網膜保護剤
Eller et al. Yellow corneal ring associated with vitamin supplementation for age-related macular degeneration
Das et al. Clinical management of eye diseases: carotenoids and their nanoformulations as choice of therapeutics
US20230210801A9 (en) Compositions for improving eye health and methods of making and using thereof
Schultz Lutein as a Contributing Modulator of Age-related Macular Degeneration
OA21150A (fr) Complément alimentaire pour la santé des yeux.
CN116115592A (zh) 维生素a或其衍生物在制备治疗青光眼疾病药物中的应用
Nicholson et al. 8A Clinical Trials in Nonneovascular Age-Related Macular Degeneration
KR20150137088A (ko) 뇌에서 카로티노이드의 신경보호 효과

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10714963

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010714963

Country of ref document: EP